Abstracts tagged "outcomes and treatment"

Abstract Number: 2912 • 2019 ACR/ARP Annual Meeting
Predictive Factors for Treatment Related Mortality and Event-Free Survival After Autologous Hematopoietic Stem Cell Transplantation for Systemic Sclerosis: Results of a Long Term Follow-up Multi-centre Study
Sandra van Bijnen ¹, Maaike Boonstra ², Els van den Ende ³, Lucia Kroft ², Bram Geurts ¹, Miranda Snoeren ¹, Anne Schouffoer ², Julia Spierings ⁴, Jacob van Laar ⁵, Thomas Huizinga ⁶, Alexandre Voskuyl ⁷, Walter van der Velden ¹, Frank van den Hoogen ³, Jeska de Vries-Bouwstra ⁶ and Madelon Vonk⁸, ¹Radboud University Nijmegen Medical Centre, Nijmegen, Gelderland, Netherlands, ²Leiden University Medical Centre, Leiden, Zuid-Holland, Netherlands, ³Department of Rheumatology, Radboud University Medical Center, Nijmegen, Gelderland, Netherlands, ⁴Utrecht Medical Centre, Utrecht, Utrecht, Netherlands, ⁵UMC Utrecht, Department of Rheumatology & Clinical Immunology, Utrecht, The Netherlands, Utrecht, Netherlands, ⁶Leiden University Medical Center, Leiden, Netherlands, ⁷Amsterdam Univiversity Medical Centre, Amsterdam, Noord-Holland, Netherlands, ⁸Department of Rheumatology, Radboud University Medical Center, Nijmegen, The Netherlands, Nijmegen, Gelderland, Netherlands
Background/Purpose: Autologous hematopoietic stemcell transplantation (HSCT) has shown to improve survival of SSc patients with poor prognosis, but is hampered by treatment related mortality (TRM).…
Abstract Number: 114 • 2017 Pediatric Rheumatology Symposium
Clinical Features and Treatment Outcomes in Down’s Arthropathy
Jordan T. Jones¹ and Leena Danawala², ¹Rheumatology Division, Children's Mercy Kansas City, Kansas City, MO, ²University of Missouri-Kansas City School of Medicine, Kansas City, MO
Background/Purpose: Crude prevalence estimates indicate Down’s Arthropathy (DA) is 3-8 times more common than juvenile idiopathic arthritis (JIA), however, DA is still largely under recognized…
Abstract Number: 85 • 2017 Pediatric Rheumatology Symposium
Characteristics of anti-MDA5 autoantibody-associated Juvenile Dermatomyositis (JDM) in North America
Gulnara Mamyrova¹, Takayuki Kishi², Ira N Targoff³, Rodolfo V Curiel¹, Frederick W Miller², Lisa G Rider^1,2 and The Childhood Myositis Heterogeneity Collaborative Study Group, ¹Division of Rheumatology, Department of Medicine, George Washington University School of Medicine and Health Sciences, Washington, DC, ²Environmental Autoimmunity Group, National Institute of Environmental Health Sciences, National Institute of Health, Bethesda, MD, ³VA Medical Center, University of Oklahoma Health Sciences Center, and Oklahoma Medical Research Foundation, Oklahoma City, OK
Background/Purpose: Anti-MDA5 Abs have been reported to associate with clinically amyopathic and classic dermatomyositis (DM), with severe progressive interstitial lung disease (ILD) and poor prognosis…
Abstract Number: 2805 • 2016 ACR/ARHP Annual Meeting
Outcomes of Lupus Nephritis Patients Following Discontinuation of Treatment
Chee Ken Cheah¹, Shirish Sangle (Joint First Author)¹, Alina Casian², Oier Barrutia¹, Munther Khamashta¹ and David D'Cruz¹, ¹Louise Coote Lupus Unit, Guy's and St. Thomas' Hospital, London, United Kingdom, ²Rheumatology, Louise Coote Lupus Unit, Guy's and St. Thomas' Hospital, London, United Kingdom
Background/Purpose: Lupus nephritis (LN) complicates 60% of systemic lupus erythematosus (SLE) patients within 5 years of diagnosis. Glucocorticoids and disease modifying immunosuppressive drugs (IS) are…
Abstract Number: 1708 • 2015 ACR/ARHP Annual Meeting
Predictors of Depression Severity in Ankylosing Spondylitis
Mark Hwang¹, MinJae Lee², Michael M. Ward³, Lianne S. Gensler⁴, Matthew A. Brown⁵, Shervin Assassi⁶, Laura A. Diekman⁷, Mohammad H. Rahbar⁸, Michael H. Weisman⁹ and John D. Reveille¹⁰, ¹Internal Medicine, University of Texas Health Science Center at Houston, Houston, TX, ²Biostatistics/Epidemiology/Research Design (BERD) Core | Center for Clinical and Translational Sciences, University of Texas Health Science Center at Houston, Houston, TX, ³NIH/NIAMS, Bethesda, MD, ⁴Medicine/Rheumatology, University of California, San Francisco, San Francisco, CA, ⁵The University of Queensland Diamantina Institute, Brisbane, Australia, ⁶Rheumatology, University of Texas Medical School at Houston, Houston, TX, ⁷Rheumatology, University of Texas Medical School, Houston, TX, ⁸The University of Texas Health Science Center at Houston, Houston, TX, ⁹Rheumatology, Cedars-Sinai Medical Center, Los Angeles, CA, ¹⁰Rheumatology, University of Texas Health Science Center at Houston, Houston, TX
Background/Purpose: Depression is a known comorbidity of ankylosing spondylitis (AS) with over one-third of AS patients affected and increased depression-rate ratio compared to the general…
Abstract Number: 1990 • 2015 ACR/ARHP Annual Meeting
Corticosteroid Use in Idiopathic Aortitis: A Systematic Review
Nancy Maltez¹ and Nataliya Milman², ¹Internal Medicine, University of Ottawa, Ottawa, ON, Canada, ²Division of Rheumatology, University of Ottawa, Ottawa, ON, Canada
Background/Purpose: Idiopathic aortitis (IA) is a poorly defined entity with no specific pathological or clinical criteria for its classification or diagnosis, except for the presence…
Abstract Number: 928 • 2014 ACR/ARHP Annual Meeting
A Multinational Study of the Epidemiology, Treatment and Outcome of Childhood Arthritis: Preliminary Data from 6,940 Patients
Alessandro Consolaro¹, Amita Aggarwal², Troels Herlin³, Olga Vougiouka⁴, Rubén Burgos-Vargas⁵, Ilonka Orban⁶, Nahid Shafaie⁷, Maria Trachana⁸, Lidia Rutkowska-Sak⁹, Ingrida Rumba-Rozenfelde¹⁰, Dimitrina Mihaylova¹¹, Alberto Martini^12,13 and Angelo Ravelli^1,14, ¹Pediatria II, Istituto Giannina Gaslini, Genova, Italy, ²Clinical Immunology, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India, ³Pediatric Rheumatology Clinic, Department of Pediatrics, Aarhus University Hospital, Aarhus, Denmark, ⁴P. A. Kyriakou Childrens Hospital of Athens University, Athens, Greece, ⁵Hospital General de Mexico, Universidad Nacional Autonoma de Mexico, Mexico City, Mexico, ⁶National Institute of Rheumatology and Physiotherapy, Budapest, Hungary, ⁷Rheumatology Research Centre, Tehran University of Medical Sciences, Tehran, Iran, ⁸Aristotle University, Thessaloniki, Greece, ⁹Institute of Rheumatology, Warsaw, Poland, ¹⁰University of Latvia, Riga, Latvia, ¹¹University Children Hospital, Sofia, Bulgaria, ¹²Istituto Giannina Gaslini, Genova, Italy, ¹³University of Genova, Genova, Italy, ¹⁴Istituto Giannina Gaslini and University of Genova, Genova, Italy
Background/Purpose The epidemiology of juvenile idiopathic arthritis (JIA) is known to be variable worldwide and the therapeutic approach to JIA is not standardized. Moreover, the…
Abstract Number: 2779 • 2014 ACR/ARHP Annual Meeting
Systemic Inflammatory and Autoimmune Manifestations Associated with Myelodysplastic Syndrome: A French Multicenter Retrospective Study
Arsene Mekinian¹, Eric Grignano¹, Thorsten Braun², Olivier Decaux³, Eric Liozon⁴, Nathalie Costedoat-Chalumeau⁵, Jean Emmanuel Kahn⁶, Mohamed Hamidou⁷, Geraldine Falgarone⁸, Olivier Lortholary⁹, Sophie Park¹⁰, Zahir Amoura¹¹, A. Mathian¹², Bruno Gombert¹³, Christian Rose¹⁴, Xavier Puechal¹⁵, David Launay¹⁶, Guillaume Denis¹⁷, Bertrand Lioger¹⁸, Anne Laure Buchdaul¹⁹, Sophie georgin Lavialle²⁰, Francois Montestruc²¹, Mohammed Omouri²², Julien Rossignol²³, Jean Marc Ziza²⁴, Pascal Cathebras²⁵, Serge Madaule²⁶, Benoit de Wazières²⁷, Nathalie Morel¹⁵, Sebastien Trouillet²⁸, Loic Raffray²⁹, Yoland Schoindre³⁰, Eric Toussirot³¹, jean Charles Piette³², Claude Gardin², Lionel Ades³³, Pierre Fenaux³³ and Olivier Fain³⁴, ¹Internal Medicine, DHUi2B Saint Antoine Hospital, paris, France, ²Haematology department Avicenne Hospital, bobigny, France, ³Department of Internal Medicine, Rennes University Hospital, Rennes, France, ⁴INTERNAL MEDICINE, DIJON, France, ⁵Internal Medicine, Department of Internal Medicine, Referral Center for Rare Autoimmune and Systemic Diseases, Hôpital Cochin, AP–HP, Université Paris Descartes, Paris, France, ⁶Internal medicine Hopital Foch, PARIS, France, ⁷CHU Hôtel Dieu, Nantes, Nantes, France, ⁸Rheumatology department Avicenne Hospital INSERM 1125, bobigny, France, ⁹Service de maladies infectieuses, Hôpital Necker-Enfants malades, AP-HP, Paris, France, ¹⁰Haematology Department, Grenoble University Hospital, grenoble, France, ¹¹Internal medicine 2, French National Reference Center for Systemic Lupus and Antiphospholipid Syndrome, Pitié-Salpêtrière Hospital (AP-HP), Paris, France, ¹²Internal Medecine Department, Pitie-Salpetriere Hospital, Paris, France, ¹³Internal Medicine, La Rochelle hospital, La Rochelle, France, ¹⁴haematology, lille, France, ¹⁵Department of Internal Medicine, Referral Center for Rare Autoimmune and Systemic Diseases, Hôpital Cochin, AP–HP, Université Paris Descartes, Paris, France, ¹⁶Service de médecine interne, Centre National de Référence de la Sclérodermie Systémique, Hôpital Claude Huriez, CHRU Lille, Lille, France, ¹⁷Internal Medicine, Rochefoucault hospital, Rochefoucault, France, ¹⁸INTERNAL MEDICINE, tours, France, ¹⁹Internal Medicine, Douai hospital, Douai, France, ²⁰Internal Medicine Department Tenon Hospital, paris, France, ²¹exystat, PARis, France, ²²Rheumatology Department Romilly Hospital, romilly, France, ²³haematology, paris, France, ²⁴Hopital Croix-Saint-Simon, Paris Cedex 20, France, ²⁵Internal Medicine, University Hospital St Etienne, St Etienne, France, ²⁶Medecine interne, Chg, Albi, France, ²⁷Department of Internal Medicine and Gerontology, Hôpital Universitaire Carémeau, Nîmes, France, Nimes, France, ²⁸INTERNAL MEDICINE, aurillac, France, ²⁹INTERNAL MEDICINE, bordeaux, France, ³⁰DHU 2iB Internal Medicine Referal Center for Autoimmune diseases Pitie Hospital, PARIS, France, ³¹Clinical Investigation Centre Biotheraoy CIC 1431, Rheumatology Department, Univesity Hospital, besancon, France, ³²INTERNAL MEDICINE, PARIS, France, ³³Haematology department Saint Louis Hospital, paris, France, ³⁴Hôpital Saint Antoine, DHU i2B, Service de Médecine Interne, paris, France
Background/Purpose: To describe characteristics, treatment and outcome of patients with systemic inflammatory or autoimmune diseases (SAID) and myelodysplastic syndrome (MDS).Methods: For this retrospective study, a…
Abstract Number: 2199 • 2014 ACR/ARHP Annual Meeting
Intravenous Immunoglobulin Therapy for Secondary Hemophagocytic Lymphohistiocytosis : A Retrospective Study of 46 Patients
Bertrand Dunogué¹, Magdalena Gerin², Claire Larroche³, Catherine Montagnier-Petrissans⁴, Loïc Guillevin⁵ and Luc Mouthon⁵, ¹Internal Medicine, National Referral Center for Rare Systemic Autoimmune Diseases, Hôpital Cochin, AP–HP, Université Paris Descartes, Paris, Paris, France, ²Internal Medicine, Hôpital Jean Verdier, Bondy, France, ³Internal Medicine, Hôpital Avicenne, Bobigny, France, ⁴Groupe d'Expert AP-HP, Paris, France, ⁵National Referral Center for Rare Systemic Autoimmune Diseases, Hôpital Cochin, AP–HP, Université Paris Descartes, Paris, Paris, France
Background/Purpose Intravenous Immunoglobulins (IVIg) have been reported as giving good results in infectious, but also auto-immune related forms of hemophagocytic lymphohistiocytosis (HLH), but only in…
Abstract Number: 1243 • 2014 ACR/ARHP Annual Meeting
Macrophage Activation Syndrome Complicating Adult Onset Still’s Disease – Single Center Experience and Literature Review
Aleksander Lenert¹ and Qingping Yao², ¹Orthopaedic and Rheumatologic Institute, Dept. of Rheumatic & Immunologic Diseases, Cleveland Clinic, Cleveland, OH, ²Rheumatic and Immunologic Dis, Cleveland Clinic, Cleveland, OH
Background/Purpose: Hemophagocytic lymphohistiocytosis (HLH) is a life threatening complication typically associated with hematologic malignancies and infections. HLH, also referred to as macrophage activation syndrome (MAS),…
Abstract Number: 1235 • 2014 ACR/ARHP Annual Meeting
Recovery of Renal Function after Corticosteroid Therapy for IgG4-Related Kidney Disease
Takako Saeki¹, Mitsuhiro Kawano², Ichiro Mizushima², Motohisa Yamamoto³, Yoshifumi Ubara⁴, Hitoshi Nakashima⁵, Yoko Wada⁶, Tomoyuki Ito⁷, Hajime Yamazaki⁷, Ichiei Narita⁶ and Takao Saito^5,8, ¹Department of Internal Medicine, Nagaoka Red Cross Hospital, Nagaoka, Japan, ²Kanazawa University Hospital, Kanazawa, Japan, ³Sapporo Medical University School of Medicine, Sapporo, Japan, ⁴Toranomon Hospital, Tokyo, Japan, ⁵Div of Nephrol & Rheumatol, Dept of Int Med, Faculty of Medicine, Fukuoka University, Fukuoka, Japan, ⁶Division of Clinical Nephrology and Rheumatology, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan, ⁷Nagaoka Red Cross Hospital, Nagaoka, Japan, ⁸General Medical Research Center, Faculty of Medicine, Fukuoka University, Fukuoka, Japan
Background/Purpose: In our earlier study of IgG4-related kidney disease (IgG4-RKD), we found that renal dysfunction, which was mostly attributable to IgG4-related tubulointerstitial nephritis, was significantly…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].